Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anquilisi
- Development stage
- Unknown
- Lead developer
- Shanxi Zhendong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IMM-H012 (anquilisi) is an orally bioavailable small molecule that acts as a dual inhibitor of phosphoinositide 3-kinase (PI3K) and the serine/threonine-protein kinase mTOR. Developed by the Institute of Materia Medica, Chinese Academy of Medical Sciences, in collaboration with Shanxi Zhendong Pharmaceutical, the compound targets the PI3K/AKT/mTOR signaling pathway, which is a critical regulator of cell growth, proliferation, and survival and is frequently hyperactivated in various malignancies. IMM-H012 is currently being evaluated in a Phase I/II clinical trial in China for the treatment of advanced solid tumors, including colorectal, gastric, lung, and breast cancers, with a particular focus on patients harboring PIK3CA mutations or PTEN alterations.
- Other names
- anquilisi
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on anquilisi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anquilisi.